Phase 3 N=511 Remission and Joint Damage Progression in Early Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Number of Participants in DAS 28 C-reactive Protein (CRP) Remission at Month 12 — 106; 59 participants — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=351 A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512)
Perennial Allergic Rhinitis
Primary: Change in 4 Nasal Symptom Score (Sneezing Attack, Rhinorrhea, Nasal Congestion, and Nasal Itching) After 2 Weeks — 7.84; 8.41; 8.27; 8.29 Units on a scale — p=0.0001
Phase 3 N=712 Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis
Osteoporosis, Postmenopausal · Back Pain · Spinal Fracture
Primary: Number of Participants Responding With at Least a 30% Reduction in 24-Hour Worst Back Pain Severity at the 6-Month Endpoint — 206; 193; 142; 143 participants — p=0.642
Phase 3 N=600 An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)
Papillomavirus Infections
Primary: Geometric Mean Titer (GMT) of Anti-HPV 6, 11, 16 , 18 at Day 1 and Month 7 (1 Month After Completion of Administration of a 6-month 3-dose Regimen of Vaccines) — 7; 7…
Phase 3 N=840 Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema
Diabetic Macular Edema
Primary: Change In Visual Acuity [Measured With Electronic-Early Treatment Diabetic Retinopathy Study (E-ETDRS)]Baseline to 2 Years. — 1; -2; -3 Letter score — p=0.02
Phase 3 N=260 Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis
Multiple Sclerosis
Primary: Number of Participants Who Were Neutralising Antibody (NAb) Positive at the Week 96 Visit. — 45 participants
Phase 3 N=427 Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder
Excessive Sleepiness
Primary: Mean Sleep Latency (Minutes) From the Multiple Sleep Latency Test (MSLT)- Average of Four Scheduled Naps Across Days 1 and 2 — 7.7; 11.7; 4.8 Minutes — p=<0.0001
Phase 3 N=219 Efficacy and Safety Study of Esomeprazole 20mg qd vs Ranitidine 150mg Bid in Patients With an NSAID-induced Gastric Ulcer
Gastric Ulcer
Primary: The Percentage of Subjects Whose Gastric Ulcer(s) (GUs) Was (Were) Healed at Week 4 After Treatment With Esomeprazole 20 mg qd and Ranitidine 150 mg Bid in Patients…
Phase 3 N=170 Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment
Type 2 Diabetes
Primary: Absolute Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) Level to Week 12 Last Observation Carried Forward (LOCF) — 8.09; 8.45; 7.80; 7.63 Percent — p=0.007
Phase 3 N=24,111 Evaluation of a Human Immunodeficiency Virus (HIV) Blood Screening Assay
Healthy Donors · HIV Positive
Primary: PRISM HIV O Plus Test Data for Specificity — 10; 15589 participants
Phase 3 N=196 6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)
Schizophrenia
Primary: Change From Baseline in Negative Symptoms of Schizophrenia Measured by the Negative Symptom Assessment (NSA) Scale Total Score — 61.5; 60.3; -15.8; -11.0 Units on a…
Phase 3 N=326 IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
Cytomegalovirus Infections
Primary: Percentage of Patients Who Developed Cytomegalovirus (CMV) Disease up to Month 12 Post-transplant — 43.6; 23.9 Percentage of patients — p=<=0.0002
Phase 3 N=116 Safety Study Comparing Phenylephrine HCL Extended Release Tablets 30 mg and Placebo (Study CL2007-07)(P07529)(COMPLETED)
Blood Pressure · Human Experimentation
Primary: Average Systolic Blood Pressure (SBP) Readings for a 5-hour Range Around the Time of Maximum Concentration (Tmax). — 118.3; 118.6 mmHg — p=0.5480
Phase 3 N=180 A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Primary: Number of Combined Unique (CU) Active Magnetic Resonance Imaging (MRI) Lesions at Week 16 — 0.9; 3.0 lesions — p=<0.001
Phase 3 N=593 Infliximab in High Need Versus Low Need Psoriasis Patients: The IHELP Study (Study P04320)(COMPLETED)
Psoriasis
Primary: Proportion of Participants Achieving a Greater Than or Equal to 75% Improvement in Psoriasis Area and Severity Index (PASI75) Score — 0.739; 0.698 Proportion of…